Almac Group Appoints Dr. Victor Diaz Perez as Head of Physical Sciences

Almac Group Appoints Dr. Victor Diaz Perez as Head of Physical Sciences

October 28, 2016

Craigavon, N.I., 26th October 2016Almac Group, the global contract development and manufacturing organization has announced the appointment of Dr. Victor Diaz Perez as Head of Physical Sciences.

Dr. Diaz will further complement the existing physical sciences team bringing considerable experience in research and development within solid state chemistry.  He will be responsible for Almac’s Solid State Chemistry and Physical Sciences business and tasked with strengthening the overarching chemical development strategy.

Before joining Almac Dr. Diaz spent ten years with Pharmorphix®, now part of Johnson Matthey Plc., a global CRO providing solid state services for the pharmaceutical and fine chemicals industry. There he worked as Projects Director before being appointed as Site Manager / Operations Director. He was also a key player in the acquisition of Pharmorphix® by Johnson Matthey Plc. from Sigma Aldrich Co. Ltd, which completed in October 2015.

Before joining Pharmorphix®, Dr. Diaz worked for over seven years as a Medicinal Chemist at Medivir AB, both within the hit identification and lead optimzation teams and, prior to that, he worked at High Force Research, Ltd providing chemical synthesis and R&D service to the pharmaceutical, agrochemical and fine chemical industries.

John Robson, VP Quality Operations at Almac Sciences commented on Dr. Diaz’s appointment: “Victor’s combined experience within physical sciences and his extensive knowledge of strategic management makes him a valuable addition to our team.  We are delighted he has accepted this role with Almac and we look forward to working together to continue to develop our global business and provide best in class, innovative drug development solutions to our growing client base.” 

Victor has a Ph.D. in Organic Chemistry from the University of Seville working on the design, synthesis and evaluation of glycomimetics of natural occurring azasugars used for the inhibition of glycosidases. He has also been awarded CChem status and recognition as a Fellow of the Royal Society of Chemistry.

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organization that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

https://www.almacgroup.com

Share

Back to news